Antibody response in patients with autoimmune inflammatory rheumatic disease after pneumococcal polysaccharide prime vaccination or revaccination
Authors' conclusion
Only 36% of patients with a non-protective antibody level achieved a protective level in response to pneumococcal vaccination. Pneumococcal vaccination within the last 5 years and MTX treatment at the time of vaccination were independently associated with a poor antibody response.
Study context
- Population
- Autoimmune inflammatory rheumatic disease (AIIRD) patients on biological disease-modifying anti-rheumatic drug (bDMARD) treatment for RA, SpA or PsA, Denmark, with a non-protective pneumococcal antibody level (geometric mean <1 μg/mL), vaccinated with pneumococcal polysaccharide vaccine (PPV23)of 301
- Participants
- 224 patients
- Exposure
- No previous PPV23 vaccination vs PPV23 vaccination <5 years ago vs ≥5 years ago
- Outcome
- Protective pneumococcal antibody level (12 serotypes) after PPV23
- Follow-up
- 3 months
Methodological detailsmultivariable logistic regression
- Multivariable logistic regression
Main finding
As reported in the abstract
Protective antibody level after vaccination
Patients achieving a protective antibody level (overall)
80
36%
Observational data: associations, not effects.
Further findings
Methotrexate (MTX) at time of vaccination and non-protective antibody level
- MTX treatment associated with a non-protective antibody level
- P < 0.001
Original publication
Antibody response in patients with autoimmune inflammatory rheumatic disease after pneumococcal polysaccharide prime vaccination or revaccination. Scand J Rheumatol. Published 20 January 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →